U.S., July 8 -- ClinicalTrials.gov registry received information related to the study (NCT07052877) titled 'The Effect of Glioblastoma PSMA Expression Following Tumour VEGF Blockade From Bevacizumab' on June 23.
Brief Summary: This trial is a single arm study for patients receiving bevacizumab for IDH-wildtype glioblastoma. Patients receiving bevacizumab (an anti-VEGF therapy) will receive PSMA scans to investigate the role of PSMA expression in glioblastoma and its relationship to VEGF expression.
Study Start Date: July, 2025
Study Type: OBSERVATIONAL
Condition:
Glioblastoma
Glioblastoma Multiforme (GBM)
Intervention:
DIAGNOSTIC_TEST: PSMA PET/CT scan
PSMA PET scan will be used to monitor changes in PSMA expression in response to b...